Tuberculosis and leprosy are chronic infectious diseases that presently affect more than 65 million people (1, 2) . Apparently the majority of individuals exposed to or infected with pathogenic mycobacteria develops effective immunity that is exclusively based on the cellular immune response, and recent evidence suggests that T helper/inducer (T4) lymphocytes are of particular importance for protection (3) (4) (5) (6) . In previous studies whole bacteria or crude bacterial extracts have been used for stimulation of heterogeneous T cell populations. Thus, the bacterial proteins recognized by mycobacteria-reactive T lymphocytes are completely unknown. Recently, a 64 kD protein antigen of Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been cloned in Escherichia coli (7), and T cell clones (TC) with reactivity to mycobacterial antigens have been established (8). It has therefore become possible to characterize defined mycobacterial antigens by their potential to stimulate distinct TC. We have used this approach to characterize the reactivity against a recombinant M. bovis BCG antigen (antigen A) of human TC that were derived from a leprosy patient by in vitro stimulation with M. leprae and from three normal PPD-reactive individuals by stimulation with BCG. This is of particular interest for vaccine development, and for the design of better-defined and more specific diagnostic skin test reagents.
by Dr. W. Brehmer, Robert-Koch Institut, Berlin, Federal Republic of Germany; and M. tuberculosis was a kind gift of Dr. J. K. Seydel, Forschungsinstitut Borstel, Borstel, Federal Republic of Germany. Cultivable mycobacteria were grown in Bacto Dubos Broth (Difco Laboratories, Detroit, M I) supplemented with BSA and Tween 80 at 37 °C under shaking conditions. Washed mycobacteria were heat-killed and ultrasonicated at 60 W (three times, 3 min each) using a Branson Sonifier B12 with microtip. For crude preparations of cell wall and cytoplasmic fractions, the sonicated material was centrifuged at 20,000 g for 20 rain and separated pellets (cell wall-enriched) and supernatants (mainly cytoplasmic proteins) were used.
Detection of M. boris BCG Protein by SDS-PAGE. 20 t~g protein of E. coli iysates and 6 ~g protein of M. bovis BCG lysate were applied to SDS-polyacrylamide gels (0) of 7.5% acrylamide. After electrophoresis (3 h at 120 V, constant voltage) the separated proteins were silver stained (NEF-982; New England Nuclear, Boston, MA).
Production of Antigen A by E. coli KIZ For the production of antigen A, we used E. coil K 12 host strain 1046 carrying the plasmids pCI857 plus pRIB 1000. Plasmid pRIB 1000 is a recombinant DNA plasmid composed of the expression plasmid pPLc236 (10) and a 4.9 kb M. bovis BCG DNA fragment. The latter DNA fragment encodes for the antigen A (7) . The expression of antigen A is low when cells are grown at 28°C due to the presence of the plasmid pCI857-encoded iambda repressor, which prevents transcription of the lambda promoter on plasmid pRIB1000. Overproduction occurs at 42°C due to inactivation of the thermolabile repressor. E. coli cells were grown to exponential phase in NZYM medium (11) at 28°C and incubated overnight at 42°C. After washing with saline, the cells were broken in a French press and centrifuged for 10 min at 10,000 g. The supernatant was used as a crude preparation of antigen A. As a control, similar cell extracts were made from E. coli KI2 1046, carrying only plasmid pCI857.
Generation of Human T Cell Clones. PBL of an Indian patient with tubercuioid leprosy classified on the basis of clinical and histopathoiogical criteria described by Ridley and Jopling (12) , and of three healthy PPD ÷ donors were prepared by flotation on Ficoll/metrizoate. Human T lymphocytes specific for mycobacterial proteins were stimulated in cultures of 1.5 × 106 cells/ml in RPMI 1640 medium supplemented with 10% screened human A or AB serum, 2 mM L-glutamine, 25 mM Hepes buffer, 2 × 10 -~ M 2-ME, 100 U/ml penicillin, and 100 t~g/ml streptomycin in the presence of 10 ~g/ml of the respective soluble antigen or 107 cells/mi heat-killed and sonicated microorganisms. PBL bulk cultures from the leprosy patient were transferred from Bombay to Freiburg for further culturing and cloning. This patient was selected from others because of his covsiderable T cell reactivity in vitro and his HLA-DR phenotype (DR3), which also occurred frequently in a panel of pretested volunteers in F~eiburg who provided APC for maintaining antigenspecific T cells. After culture for 7 d in 24-well flat-bottomed microtiter trays (Nunc, Roskilde, Denmark), IL-2 was added (15 U/ml, Biotest, Frankfurt, Federal Republic of Germany) for 4 d. Subsequently, viable cells were separated on Ficoll/metriozate and plated at one cell per microculture well of 96-well round-bottom trays (Nunc) in medium containing 60 U/ml IL-2 together with 5 × 104 autologous irradiated (4,000 rad) PBL, or plated at five cells]well with IL-2 (60 U]ml) and HLA-D-matched irradiated (4,000 rad) PBL as APC. Both cultures also contained 10 #g/ml mycobacteriai protein in a total volume of 100 #1. T cells from PPD-reactive donors were immediately cloned after the initial stimulation. After 10-14 d, growing clones could be transferred. Subclones were obtained by recloning. Every 3-4 d, fresh IL-2 was added, and irradiated pooled feeders were added every 7 d. Before use in assay systems, TC were rested 6-7 d after the last addition of feeder cells. Phenotype analysis was performed cytofluorometrically with the mAb OKT3, OKT4, OKT8, (Ortho Diagnostics, Westwood, MA), Proliferative Assay. 104 TC were incubated in 200-t~l triplicate cultures together with 5 × 104 irradiated (4,000 rad) HLA-D-matched PBL as APC, plus antigen, in roundbottom microtiter wells (Nunc). Antigen concentrations are indicated in the legend to 
Results and Discussion
A gene bank of M. bovis BCG has been constructed (7) in E. coli by cloning mycobacterium DNA fragments into a lambda cloning vehicle. Clones of this library have been screened for the production of mycobacterial antigens by using a polyclonal anti-M, bovis BCG antiserum. ~50% of the antigen-positive clones produced one particular mycobacterial protein antigen, designated antigen A. This protein has an Mr of 64 kD on SDS-PAGE, and a variety of mycobacterial species as well as PPD preparations contain (7) proteins crossreacting with antigen A. In Fig. 1 , at 64 kD, a prominent band can be seen in lysates of both BCG and E. coli expressing antigen A. Densitometric determinations showed that antigen A is ~2% of total protein in these crude extracts.
We have tested the ability of antigen A to stimulate human T4 clones using this crude lysate. 105 TC from a leprosy patient in the tuberculoid phase of the disease have been established initially by stimulation with a mixture ofM. leprae proteins and PPD (8). 11 T4 clones specific for either PPD (2 of 11), M. leprae protein (5 of 11), or crossreactive to both preparations (4 of 11) were selected because of their considerable growth after specific stimulation. All of them had the phenotype T3 +, T8-, T4 +. The four crossreactive TC could also be stimulated by BCG. In Table I , proliferative responses of five representative TC are shown. 2G2 and 2D1, which expressed selective reactivity towards either M. leprae protein or PPD, could not be restimulated by antigen A. However, two of the three crossreactive TC (shown in Table I ) that reacted with both PPD and 34. leprae antigen were restimulated by antigen A. The response of clones 1H 11 and 4F1 to 10 #g/ml PPD, 10 #g/ml M. leprae protein, or 20/~g/ml of the E. coli lysate (containing ~0.4 ~g/ml protein A), respectively, was comparable, suggesting that the antigen recognized by these TC was identical in the different were calculated as test cpm divided by control cpm (see Table I ; cpm values with OVA). Note that stimulation indices are shown in logarithmic scale.
antigen preparations. The control E. coli extract had no mitogenic effect for these TC (Table I) . TC were not stimulated by antigen alone, indicating dependence on presentation by APC (data not shown). In Fig. 2 , proliferation profiles of TC 1H11, 4F1, 2C11, and 2D1 in response to a variety of mycobacterial antigens are shown in a logarithmic scale. Clone 2C11 expressed a broad reactivity pattern to several mycobacterial antigens including M. avium and M. intracellulare, whereas clone 2D1 showed a distinct and more restricted pattern. A third type of stimulation profile was shared by TC 1Hll and 4F1, both reactive to antigen A. These similarities in their proliferation profiles indicate that the same antigen was recognized by TC 1H 11 and 4F 1. Panels of BCG-reactive TC were established from three healthy PPD + donors to estimate the proportion of antigen A-reactive T cells among them. The initial stimulation with BCG was followed immediately by cloning under limitingdilution conditions to minimize in vitro selection. The frequency of antigen Areactive TC varied. Out of those TC that could be restimulated significantly by BCG, in three distinct donors, 45 of 66, 3 of 12, and none of 8, respectively, were reactive with antigen A, suggesting that this antigen for some individuals may be an important T cell antigen.
Recently, a recombinant protein of M. bovis BCG has been produced (7) , and this offered the possibility of defining T cell antigens by means of mycobacteriareactive TC (8) . It was encouraging to find that whole E. coli lysates containing the relevant antigen did not exert suppressive effects for specific stimulation of TC (see Table I ), thus facilitating screening assays with transfected proteins without need for prior purification.
The individual stimulation patterns of TC 2H 11 and 4F1 in the presence of a variety of crude mycobacterial extracts were similar, indicating that these TC recognized the same antigen. This approach may be useful for defining major T cell antigens by comparing stimulation profiles of a large number of TC established under minimal in vitro selection pressure, with undefined antigen extracts. TC with the most frequent stimulation pattern should recognize a major T cell antigen, and representative TC could be used for identification of the homologous antigen in different preparations during the course of purification.
Although it seems suggestive, the observation that many T cells recognize the same antigen does not necessarily imply a protective role for this antigen. Therefore, additional criteria are needed. Acquired resistance against mycobacteria depends on specific T lymphocytes (1, 2) , and present evidence suggests that these are T4 ÷, T8-cells that produce IFN-3, and/or macrophage activating factor (3) (4) (5) (6) . Therefore, identification of protective antigens might be possible with TC that meet these requirements. Our antigen A-reactive TC, 2H11 and 4F1, express the T4 ÷, T8-phenotype, and after stimulation with antigen secrete IFN-3, (8), and hence may exert antibacterial activity. Besides this deductive characterization, at present there is no other way for defining T cell antigens as protective at the preclinical level. Fortunately, a considerable number of BCGreactive TC from healthy individuals and from a leprosy patient could be stimulated. However, further investigations on frequencies of antigen A-reactive TC in patients with different mycobacterial diseases are needed to estimate the role and the potential use of antigen A as T cell antigen in these diseases.
Summary
A recombinant 64 kD protein ofMycobacterium bovis bacillus Calmette-Guerin (BCG) (antigen A), which amounted to ~2% of an E. coli lysate, was tested for its capacity to stimulate human T4 clones reactive to mycobacterial proteins. Two out of four crossreactive clones, established from a patient with tuberculoid leprosy, which could be stimulated by protein preparations of M. leprae and M. tuberculosis, and by particulate M. bovis BCG were also reactive to antigen A without further enrichment from E. coli lysate. In addition, BCG-reactive T cell clones from two of three healthy PPD ÷ donors reacted with antigen A. This finding shows that human T cell clones may be useful for probing gene-cloned proteins of potential value for vaccination against diseases where protection is mediated exclusively by T cells.
